BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2706010)

  • 1. Microsomal warfarin binding and vitamin K 2,3-epoxide reductase.
    Thijssen HH; Baars LG
    Biochem Pharmacol; 1989 Apr; 38(7):1115-20. PubMed ID: 2706010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity.
    Thijssen HH; Baars LG; Vervoort-Peters HT
    Br J Pharmacol; 1988 Nov; 95(3):675-82. PubMed ID: 3207986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and vitamin K-dependent carboxylase in various tissues of the rat.
    de Boer-van den Berg MA; Thijssen HH; Vermeer C
    Biochim Biophys Acta; 1986 Oct; 884(1):150-7. PubMed ID: 3490277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of warfarin resistance and liver microsomal vitamin K epoxide reductase activity in rats.
    MacNicoll AD
    Biochim Biophys Acta; 1985 May; 840(1):13-20. PubMed ID: 3995080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin resistance. Vitamin K epoxide reductase of Scottish resistance genes is not irreversibly blocked by warfarin.
    Thijssen HH
    Biochem Pharmacol; 1987 Sep; 36(17):2753-7. PubMed ID: 3632704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes.
    Fasco MJ; Principe LM; Walsh WA; Friedman PA
    Biochemistry; 1983 Nov; 22(24):5655-60. PubMed ID: 6652076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin resistance in a Chicago strain of rats.
    Misenheimer TM; Suttie JW
    Biochem Pharmacol; 1990 Nov; 40(9):2079-84. PubMed ID: 2242035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of S-warfarin administration on vitamin K 2,3-epoxide reductase activity in liver, kidney and testis of the rat.
    Thijssen HH; Janssen CA; Drittij-Reijnders MJ
    Biochem Pharmacol; 1986 Oct; 35(19):3277-82. PubMed ID: 3768021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that warfarin anticoagulant action involves two distinct reductase activities.
    Fasco MJ; Hildebrandt EF; Suttie JW
    J Biol Chem; 1982 Oct; 257(19):11210-2. PubMed ID: 6811577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solubilization and characterization of vitamin K epoxide reductase from normal and warfarin-resistant rat liver microsomes.
    Hildebrandt EF; Preusch PC; Patterson JL; Suttie JW
    Arch Biochem Biophys; 1984 Feb; 228(2):480-92. PubMed ID: 6696443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase.
    Thijssen HH; Baars LG
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1082-8. PubMed ID: 3694526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue distribution of selective warfarin binding sites in the rat.
    Thijssen HH; Baars LG
    Biochem Pharmacol; 1991 Nov; 42(11):2181-6. PubMed ID: 1958236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-purification of microsomal epoxide hydrolase with the warfarin-sensitive vitamin K1 oxide reductase of the vitamin K cycle.
    Guenthner TM; Cai D; Wallin R
    Biochem Pharmacol; 1998 Jan; 55(2):169-75. PubMed ID: 9448739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat.
    Fasco MJ; Principe LM
    J Biol Chem; 1982 May; 257(9):4894-901. PubMed ID: 7068669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsomal lipoamide reductase provides vitamin K epoxide reductase with reducing equivalents.
    Thijssen HH; Janssen YP; Vervoort LT
    Biochem J; 1994 Jan; 297 ( Pt 2)(Pt 2):277-80. PubMed ID: 8297331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin K metabolism and vitamin K1 status in human liver samples: a search for inter-individual differences in warfarin sensitivity.
    Thijssen HH; Drittij-Reijnders MJ
    Br J Haematol; 1993 Aug; 84(4):681-5. PubMed ID: 8217828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapachol inhibition of vitamin K epoxide reductase and vitamin K quinone reductase.
    Preusch PC; Suttie JW
    Arch Biochem Biophys; 1984 Nov; 234(2):405-12. PubMed ID: 6497379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue distribution and warfarin sensitivity of vitamin K epoxide reductase.
    Hazelett SE; Preusch PC
    Biochem Pharmacol; 1988 Mar; 37(5):929-34. PubMed ID: 3345202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin-K-dependent proteins in microsomes of primary Lewis lung tumors.
    Wilson AC; Fasco MJ
    Int J Cancer; 1986 Dec; 38(6):877-82. PubMed ID: 3793264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a warfarin-sensitive protein component in a 200S rat liver microsomal fraction catalyzing vitamin K and vitamin K 2,3-epoxide reduction.
    Lee JJ; Principe LM; Fasco MJ
    Biochemistry; 1985 Dec; 24(25):7063-70. PubMed ID: 4084561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.